NCT01560416 2026-03-03
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
5 trialsNCT01579994 2020-12-30
Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01551693 2017-04-12
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00687934 2014-09-18
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
Phase 1 Completed
NCT00688116 2014-09-18
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
Phase 1 Unknown